Belite Bio (BLTE)

• Market cap: $1.82B
• 1 day: -1.54%
• 5 days: -3.13%
• 1 month: -16.83%
• 3 months: 0.34%
• 6 months: 0.71%
• Year to date: -12.91%
• 1 year: 74.45%
• 5 years: 432.58%
• 10 years: 432.58%
• Sector: Healthcare
• Industry: Biotechnology

About: Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.

Employees: 25

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

383% more capital invested

Capital invested by funds: $3.69M [Q3] → $17.8M (+$14.1M) [Q4]

350% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 2

47% more funds holding

Funds holding: 15 [Q3] → 22 (+7) [Q4]

20% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 5

0.67% more ownership

Funds ownership: 0.26% [Q3] → 0.92% (+0.67%) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $80 42% upside
• Avg. target: $90 60% upside
• High target: $100 77% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Benchmark Bruce Jackson 28% 1-year accuracy 13 / 47 met price target	42% upside $80	Buy Reiterated	26 Mar 2025
HC Wainwright & Co. Yi Chen 27% 1-year accuracy 46 / 173 met price target	77% upside $100	Buy Reiterated	18 Mar 2025